Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Any medication powerful enough to rapidly alleviate treatment-resistant depression warrants careful scrutiny of its safety profile — especially when used repeatedly over time. Ketamine has demonstrated remarkable antidepressant potential, but patients and clinicians alike need clear, evidence-based answers about what side effects to expect and whether long-term use carries meaningful risks. A comprehensive systematic review published in The Lancet Psychiatry provides the most thorough assessment to date.
Short B and colleagues published a systematic review in The Lancet Psychiatry in 2018 (PMID: 28864327) examining side effects associated with ketamine use in the treatment of depression. The review synthesized data from 60 studies encompassing both single-dose and repeated-dose protocols, providing a broad view of ketamine's safety profile across different administration routes, doses, and treatment durations.
The most commonly reported acute side effects were dissociative symptoms, dizziness, nausea, headache, and transient increases in blood pressure and heart rate. These effects were generally mild to moderate in severity and self-limiting, typically resolving within one to two hours after administration. Dissociative experiences — feelings of unreality, perceptual distortions, or out-of-body sensations — were dose-dependent and more pronounced with intravenous administration compared to other routes.
Regarding longer-term concerns, the review found that the evidence base was more limited but did not reveal significant cognitive impairment, persistent psychotic symptoms, or organ damage at the subanesthetic doses used in psychiatric treatment. This stands in contrast to the well-documented harms associated with chronic recreational ketamine abuse at much higher doses, which can include bladder toxicity (ulcerative cystitis), liver changes, and cognitive deficits. The distinction between supervised clinical dosing and unsupervised recreational use is critical — the doses, frequency, and context differ enormously. The review did note that more long-term data from controlled studies is needed, as most psychiatric ketamine research has involved treatment periods of weeks to months rather than years.
For physicians prescribing ketamine off-label for depression, the Short et al. review provides a useful framework for informed consent conversations. The acute side effects are predictable, manageable, and transient. Blood pressure monitoring during and after sessions is warranted, particularly for patients with cardiovascular risk factors. Dissociative effects, while sometimes uncomfortable, have not been linked to lasting psychological harm in clinical settings and may actually correlate with treatment response in some studies.
The longer-term safety question remains the area of greatest uncertainty. Because ketamine has been used in psychiatry for a relatively short period compared to drugs like lithium or SSRIs, decades-long safety data simply does not yet exist. What we can say is that at the subanesthetic doses used in psychiatric practice — typically a fraction of what would be used for anesthesia — the safety signals observed to date are reassuring. Periodic monitoring of liver and bladder function may be prudent for patients on extended maintenance protocols, though clinical guidelines vary on this point.
The abuse potential of ketamine is real but appears to be lower in the structured clinical context. Patients receiving physician-supervised treatment at prescribed doses, with appropriate screening for substance use history, represent a fundamentally different risk profile from recreational users.
If you are considering ketamine therapy, understanding the side effect profile can help you make an informed decision and prepare for what to expect. During sessions, you may experience mild dissociation, dizziness, or nausea — these are normal and temporary. Your physician should monitor your blood pressure and will typically have you rest until these effects subside before you resume normal activities.
For ongoing treatment, open communication with your prescribing physician is essential. Report any urinary symptoms, cognitive changes, or new psychological symptoms promptly. Regular check-ins allow your physician to adjust dosing, frequency, and monitoring based on your individual response. The goal is to find the minimum effective dose and frequency that maintains your improvement while minimizing exposure.
A comprehensive systematic review found that ketamine side effects at psychiatric doses are generally mild, transient, and manageable, with no significant evidence of lasting harm in clinical settings. Long-term data remains limited, making ongoing physician oversight and periodic monitoring important components of safe treatment.
Reference: Short B, et al. "Side-effects associated with ketamine use in depression: a systematic review." The Lancet Psychiatry. 2018;5(1):65-78. PMID: 28864327.
If you're considering ketamine therapy, Isha Health offers physician-led at-home treatment via telemedicine in California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, and Washington. No in-person visit required.
